Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
159M
-
Number of holders
-
204
-
Total 13F shares, excl. options
-
93.8M
-
Shares change
-
+1.01M
-
Total reported value, excl. options
-
$1.41B
-
Value change
-
+$45.7M
-
Put/Call ratio
-
0.66
-
Number of buys
-
107
-
Number of sells
-
-90
-
Price
-
$15.04
Significant Holders of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) as of Q1 2023
264 filings reported holding TGTX - TG THERAPEUTICS, INC. - COMMON STOCK as of Q1 2023.
TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) has 204 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 93.8M shares
of 159M outstanding shares and own 59.08% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (13.4M shares), Darwin Global Management, Ltd. (10.5M shares), BlackRock Inc. (8.85M shares), STATE STREET CORP (7.64M shares), FMR LLC (5.82M shares), Jefferies Financial Group Inc. (5.1M shares), WELLINGTON MANAGEMENT GROUP LLP (3.33M shares), ALKEON CAPITAL MANAGEMENT LLC (2.69M shares), GEODE CAPITAL MANAGEMENT, LLC (2.68M shares), and MILLENNIUM MANAGEMENT LLC (2.63M shares).
This table shows the top 204 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.